Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-79635322 in Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis
NCT05652335Phase 1Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2022
- Primary completion
- Apr 2027
- Modality
- Trispecific Antibodies, T-cell Engagers
- Countries
- 7
01
Overview
Phase 1, open-label trial of ramantamig in multiple myeloma (MM) and light-chain amyloidosis (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Dose-limiting Toxicity, Adverse Events and 1 more. Started Nov 2022; status: recruiting.
02
Drugs
ramantamig
03
Conditions
multiple myeloma (MM)light-chain amyloidosis
Beyond the preview
Go deeper on NCT05652335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05652335.